Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of biological marker to diagnosis of lung adenocarcinoma

A technology of biomarker and lung adenocarcinoma, applied in the field of disease diagnosis, can solve problems such as insufficiency and achieve the effect of improving survival rate

Inactive Publication Date: 2019-10-15
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But the current early detection methods are obviously insufficient. According to NIH data, only 16% of newly diagnosed lung cancer patients have localized tumors, and others have more or less spread to lymph nodes or distant metastases, so this field is still Favorable biomarkers that can be effectively used for lung adenocarcinoma screening and diagnosis are needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biological marker to diagnosis of lung adenocarcinoma
  • Application of biological marker to diagnosis of lung adenocarcinoma
  • Application of biological marker to diagnosis of lung adenocarcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 QPCR verification of related differentially expressed genes

[0041] 1. Collection of samples

[0042] 59 cases of lung adenocarcinoma tissue and 59 adjacent tissues were collected, and all samples were placed in cryopreservation tubes with RNA protection solution immediately after isolation, and stored in a -80°C refrigerator within 30 minutes. The entire operation and storage The process follows the enzyme-free principle.

[0043] 2. Preparation of RNA samples

[0044] Total RNA was extracted from lung adenocarcinoma tissues and paracancerous tissues by TRIzol RNA extraction method.

[0045] (1) Pre-cool the mortar with liquid nitrogen, put the tissue sample into the mortar with liquid nitrogen, and fully grind the tissue sample into powder under liquid nitrogen;

[0046] (2) Transfer the sample powder into a 2.0ml EP tube filled with TRIzol lysate, (50mg of tissue sample can be added to each ml of lysate), shake vigorously, mix well, and lay flat at room...

Embodiment 2

[0081] Example 2 Candidate gene ROC curve analysis

[0082] 1. ROC curve analysis

[0083] Use the pROC package of R language to analyze the receiver operating characteristics of S100P, EEF1A2, MUC3A or CSF3, calculate the binomial exact confidence space, draw the ROC curve, and calculate the area under the curve.

[0084] 2. Results

[0085] The results are shown in Table 1. The AUC values ​​of the area under the ROC curve of S100P, EEF1A2, and MUC3A in patients with lung adenocarcinoma were 0.789428, 0.871876, and 0.825768, respectively. The combination of S100P, EEF1A2 and MUC3A has the highest AUC value of 0.955473, indicating that the combined diagnosis of any two or three of these three genes has higher accuracy than single diagnosis. In summary, the combination of two or three of S100P, EEF1A2, and MUC3A can be used for early diagnosis of lung adenocarcinoma.

[0086] Table 1 AUC values ​​of candidate genes combined application

[0087]

[0088]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a biological marker to diagnosis of lung adenocarcinoma. The biological marker includes two or three of S100P, EEF1A2 or MUC3A. Particularly, the invention provides an application of a detection reagent of the biological marker to preparation of products for diagnosis of the lung adenocarcinoma and the risk assessment of the occurrence of the lung adenocarcinoma. Experiment proves that compared with normal lung tissue, lung adenocarcinoma tissue has the advantages that the gene expression of the S100P, the EEF1A2 or the MUC3A is significantly increased. The ROC curve analysis shows that the genes are in united application to have higher AUC value. According to the research findings disclosed by the invention, the S100P, the EEF1A2 or the MUC3A canbe in united application to the diagnosis of the lung adenocarcinoma.

Description

technical field [0001] The invention belongs to the field of disease diagnosis and relates to the application of biomarkers in the diagnosis of lung adenocarcinoma, in particular to the application of S100P, EEF1A2 or MUC3A in the diagnosis of lung adenocarcinoma. Background technique [0002] Worldwide, lung cancer is the leading cause of cancer morbidity and mortality. In 2018, there were 2.1 million newly diagnosed cases of lung cancer and 1.8 million deaths, accounting for nearly 1 / 5 (18.4%) of cancer deaths. Among men, lung cancer is the leading cause of death in most countries in Eastern Europe and in some countries in East Asia (China). Lung cancer in women is the leading cause of cancer death in 28 countries. Non-small cell lung cancer (NSCLC) is one of the most common tumors in developed countries and the leading cause of cancer death worldwide. About 80% of lung cancers are NSCLC, including lung adenocarcinoma (LUAD, 50-60%) and lung squamous cell carcinoma (LUS...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886C12Q2600/158G01N33/57423G01N33/57484
Inventor 宋宏涛
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com